RT Journal Article
T1 FGF23, Biomarker or Target?
A1 Rodelo-Haad, Cristian
A1 Santamaria, Rafael
A1 Muñoz-Castañeda, Juan R
A1 Pendon-Ruiz de Mier, M Victoria
A1 Martin-Malo, Alejandro
A1 Rodriguez, Mariano
K1 Calcium
K1 Chronic kidney disease
K1 Dialysis
K1 Fibroblast growth factor 23 (FGF23)
K1 Parathyroid hormone
K1 Phosphate
AB Fibroblast growth factor 23 (FGF23) plays a key role in the complex network between the bones and other organs. Initially, it was thought that FGF23 exclusively regulated phosphate and vitamin D metabolism; however, recent research has demonstrated that an excess of FGF23 has other effects that may be detrimental in some cases. The understanding of the signaling pathways through which FGF23 acts in different organs is crucial to develop strategies aiming to prevent the negative effects associated with high FGF23 levels. FGF23 has been described to have effects on the heart, promoting left ventricular hypertrophy (LVH); the liver, leading to production of inflammatory cytokines; the bones, inhibiting mineralization; and the bone marrow, by reducing the production of erythropoietin (EPO). The identification of FGF23 receptors will play a remarkable role in future research since its selective blockade might reduce the adverse effects of FGF23. Patients with chronic kidney disease (CKD) have very high levels of FGF23 and may be the population suffering from the most adverse FGF23-related effects. The general population, as well as kidney transplant recipients, may also be affected by high FGF23. Whether the association between FGF23 and clinical events is causal or casual remains controversial. The hypothesis that FGF23 could be considered a therapeutic target is gaining relevance and may become a promising field of investigation in the future.
PB MDPI
YR 2019
FD 2019-03-19
LK http://hdl.handle.net/10668/13755
UL http://hdl.handle.net/10668/13755
LA en
NO Rodelo-Haad C, Santamaria R, Muñoz-Castañeda JR, Pendón-Ruiz de Mier MV, Martin-Malo A, Rodriguez M. FGF23, Biomarker or Target? Toxins (Basel). 2019 Mar 22;11(3):175
DS RISalud
RD Apr 19, 2025